151 related articles for article (PubMed ID: 33691360)
1. [The impact of CD8 and CTLA-4 expression on histopathological character and survival in mesothelioma].
Yu M; Yu M; Ying SB; Yuan XY; Jiang ZQ; Lou JL; Zhu LJ; Zhang X
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2021 Feb; 39(2):85-90. PubMed ID: 33691360
[No Abstract] [Full Text] [Related]
2. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic T-lymphocyte-associated protein 4 in gastric cancer: Prognosis and association with PD-L1 expression.
Pereira MA; de Castria TB; Ramos MFKP; Dias AR; Cardili L; de Moraes RDR; Zilberstein B; Nahas SC; Ribeiro U; de Mello ES
J Surg Oncol; 2021 Dec; 124(7):1040-1050. PubMed ID: 34255356
[TBL] [Abstract][Full Text] [Related]
4. CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma.
Wu L; Yun Z; Tagawa T; Rey-McIntyre K; de Perrot M
Mol Cancer Ther; 2012 Aug; 11(8):1809-19. PubMed ID: 22584123
[TBL] [Abstract][Full Text] [Related]
5. Clinical Implications of Cytotoxic T Lymphocyte Antigen-4 Expression on Tumor Cells and Tumor-Infiltrating Lymphocytes in Extrahepatic Bile Duct Cancer Patients Undergoing Surgery Plus Adjuvant Chemoradiotherapy.
Lim YJ; Koh J; Kim K; Chie EK; Kim S; Lee KB; Jang JY; Kim SW; Oh DY; Bang YJ
Target Oncol; 2017 Apr; 12(2):211-218. PubMed ID: 28084572
[TBL] [Abstract][Full Text] [Related]
6. Characterization of LAG-3, CTLA-4, and CD8
Wang W; Chen D; Zhao Y; Zhao T; Wen J; Mao Y; Chen C; Sang Y; Zhang Y; Chen Y
Ann Transl Med; 2019 Dec; 7(23):776. PubMed ID: 32042792
[TBL] [Abstract][Full Text] [Related]
7. NK- and T-cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti-CTLA-4 therapy.
Sottile R; Tannazi M; Johansson MH; Cristiani CM; Calabró L; Ventura V; Cutaia O; Chiarucci C; Covre A; Garofalo C; Pontén V; Tallerico R; Frumento P; Micke P; Maio M; Kärre K; Carbone E
Int J Cancer; 2019 Oct; 145(8):2238-2248. PubMed ID: 31018250
[TBL] [Abstract][Full Text] [Related]
8. Effect of asbestos exposure on differentiation and function of cytotoxic T lymphocytes.
Kumagai-Takei N; Nishimura Y; Maeda M; Hayashi H; Matsuzaki H; Lee S; Yoshitome K; Ito T; Otsuki T
Environ Health Prev Med; 2020 Oct; 25(1):59. PubMed ID: 33032525
[TBL] [Abstract][Full Text] [Related]
9. [Neutrophils mediate T lymphocyte function in septic mice via the CD80/cytotoxic T lymphocyte antigen-4 signaling pathway].
Sun R; Huang J; Liu L; Yang Y; Song M; Shao Y; Li L; Sun B
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2021 Jul; 33(7):849-854. PubMed ID: 34412756
[TBL] [Abstract][Full Text] [Related]
10. CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells.
Zhou J; Bashey A; Zhong R; Corringham S; Messer K; Pu M; Ma W; Chut T; Soiffer R; Mitrovich RC; Lowy I; Ball ED
Biol Blood Marrow Transplant; 2011 May; 17(5):682-92. PubMed ID: 20713164
[TBL] [Abstract][Full Text] [Related]
11. [Distribution and Clinical Significance of CTLA-4, PD-1 and PD-L1 in Peripheral Blood of Patients with Small Cell Lung Cancer].
Li H; Liu Y; Liu Y; Liu J; Zhao D; Wang Y; Cheng Y
Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):755-760. PubMed ID: 29167005
[TBL] [Abstract][Full Text] [Related]
12. CD4+ and CD8+ T cells expressing FoxP3 in HIV-infected patients are phenotypically distinct and influenced by disease severity and antiretroviral therapy.
Lim A; French MA; Price P
J Acquir Immune Defic Syndr; 2009 Jul; 51(3):248-57. PubMed ID: 19363449
[TBL] [Abstract][Full Text] [Related]
13. IMP3 as a prognostic biomarker in patients with malignant peritoneal mesothelioma.
Hui S; Guo-Qi Z; Xiao-Zhong G; Chun-Rong L; Yu-Fei L; Dong-Liang Y
Hum Pathol; 2018 Nov; 81():138-147. PubMed ID: 30031101
[TBL] [Abstract][Full Text] [Related]
14. SS1P Immunotoxin Induces Markers of Immunogenic Cell Death and Enhances the Effect of the CTLA-4 Blockade in AE17M Mouse Mesothelioma Tumors.
Leshem Y; King EM; Mazor R; Reiter Y; Pastan I
Toxins (Basel); 2018 Nov; 10(11):. PubMed ID: 30441807
[TBL] [Abstract][Full Text] [Related]
15. The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Kusamura S; Torres Mesa PA; Cabras A; Baratti D; Deraco M
Ann Surg Oncol; 2016 May; 23(5):1468-73. PubMed ID: 26572754
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical Evaluation of Minichromosome Maintenance Protein 7 (MCM7), Topoisomerase IIα, and Ki-67 in Diffuse Malignant Peritoneal Mesothelioma Patients Using Tissue Microarray.
Deraco M; Cabras A; Baratti D; Kusamura S
Ann Surg Oncol; 2015 Dec; 22(13):4344-51. PubMed ID: 25777091
[TBL] [Abstract][Full Text] [Related]
17. Prognostic influence of tumor microenvironment after hypofractionated radiation and surgery for mesothelioma.
de Perrot M; Wu L; Cabanero M; Perentes JY; McKee TD; Donahoe L; Bradbury P; Kohno M; Chan ML; Murakami J; Keshavjee S; Tsao MS; Cho BCJ
J Thorac Cardiovasc Surg; 2020 May; 159(5):2082-2091.e1. PubMed ID: 31866087
[TBL] [Abstract][Full Text] [Related]
18. Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma.
Anraku M; Cunningham KS; Yun Z; Tsao MS; Zhang L; Keshavjee S; Johnston MR; de Perrot M
J Thorac Cardiovasc Surg; 2008 Apr; 135(4):823-9. PubMed ID: 18374762
[TBL] [Abstract][Full Text] [Related]
19. Functional properties of CD8(+) lymphocytes in patients with pleural plaque and malignant mesothelioma.
Kumagai-Takei N; Nishimura Y; Maeda M; Hayashi H; Matsuzaki H; Lee S; Kishimoto T; Fukuoka K; Nakano T; Otsuki T
J Immunol Res; 2014; 2014():670140. PubMed ID: 25045719
[TBL] [Abstract][Full Text] [Related]
20. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells.
Schuberth PC; Hagedorn C; Jensen SM; Gulati P; van den Broek M; Mischo A; Soltermann A; Jüngel A; Marroquin Belaunzaran O; Stahel R; Renner C; Petrausch U
J Transl Med; 2013 Aug; 11():187. PubMed ID: 23937772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
